Phase II study of weekly high dose fluorouracil in previously treated patients, with metastatic colorectal cancer

Wilmosh Mermershtain, K. Lavrenkov, Y. Cohen

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD- 5FU) in previously treated patients (pts) with metastatic colorectal cancer. Previously treated and failed pts with histologically confirmed, measurable metastatic colorectal cancer, performance status (WHO) 0-2 and adequate bone marrow function were eligible for treatment. Patients received 5FU-(2.6 g/m2) as a 24-hour continuous infusion. Treatment was repeated weekly. A total of 202 cycles were given. Eighteen pts were enrolled. No pts achieved objective response. In 6 pts (33%), after 4 weeks of treatments, CEA level decreased 25% or more, and after 8 weekly treatments it rose again. Mild myelosuppression rarely occurred. Grade 1 nausea and vomiting occurred in 2 pts and Grade 1 diarrhea occurred in 2 pts. Mucositis was not observed. Conclusion: In our experience single agent, weekly, high dose 5-FU is well tolerated, but is ineffective as second-line treatment for metastatic colorectal cancer, and has only a marginal effect on CEA level.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalJournal of Chemotherapy
Volume12
Issue number2
DOIs
StatePublished - 1 Jan 2000
Externally publishedYes

Keywords

  • Colorectal cancer
  • Fluorouracil
  • High dose fluorouracil
  • Metastatic colorectal cancer
  • Phase II study

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Phase II study of weekly high dose fluorouracil in previously treated patients, with metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this